RT Journal Article
SR Electronic
T1 Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: In Vitro and In Vivo Studies
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4947
OP 4960
DO 10.21873/anticanres.14498
VO 40
IS 9
A1 HSIANG LAI CHEN
A1 JINY YIN GONG
A1 SHIH-CHAO LIN
A1 SHIMING LI
A1 YU-CHIH CHIANG
A1 JUI-HSIANG HUNG
A1 CHIEH-CHI YEN
A1 CHI-CHIEN LIN
YR 2020
UL http://ar.iiarjournals.org/content/40/9/4947.abstract
AB Background/Aim: This study aimed to investigate the anticancer effects and potential mechanisms of sclareol in a human small cell lung carcinoma (SCLC) cell line. Materials and Methods: Cell viability was determined by the MTT assay. Cell cycle, apoptosis and caspase activity were evaluated by flow cytometry. Cell cycle and DNA damage related protein expression was determined by western blotting. In vivo evaluation of sclareol was carried out in xenografted tumor mice models. Results: Sclareol significantly reduced cell viability, induced G1 phase arrest and subsequently triggered apoptosis in H1688 cells. In addition, this sclareol-induced growth arrest was associated with DNA damage as indicated by phosphorylation of H2AX, activation of ATR and Chk1. Moreover, in vivo evaluation of sclareol showed that it could inhibit tumor weight and volume in a H1688 xenograft model. Conclusion: Sclareol might be a novel and effective therapeutic agent for the treatment of SCLC patients.